Paul Maroni
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 38 | 2023 | 940 | 4.290 |
Why?
| Prostatectomy | 8 | 2019 | 100 | 1.710 |
Why?
| Testicular Neoplasms | 7 | 2023 | 95 | 1.270 |
Why?
| Urology | 3 | 2020 | 48 | 0.970 |
Why?
| Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 60 | 0.790 |
Why?
| Embolism | 1 | 2021 | 43 | 0.790 |
Why?
| Urethra | 1 | 2021 | 58 | 0.780 |
Why?
| Laser Therapy | 1 | 2021 | 104 | 0.730 |
Why?
| Androgen Antagonists | 3 | 2016 | 70 | 0.720 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 969 | 0.540 |
Why?
| Kidney Medulla | 2 | 2005 | 32 | 0.520 |
Why?
| Early Detection of Cancer | 5 | 2023 | 360 | 0.500 |
Why?
| Neoadjuvant Therapy | 2 | 2021 | 333 | 0.440 |
Why?
| Male | 55 | 2023 | 57801 | 0.420 |
Why?
| Urination Disorders | 1 | 2011 | 13 | 0.410 |
Why?
| Prostate-Specific Antigen | 8 | 2020 | 156 | 0.410 |
Why?
| Prostate | 7 | 2023 | 158 | 0.380 |
Why?
| Oxalates | 2 | 2008 | 10 | 0.350 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2014 | 1244 | 0.340 |
Why?
| Neoplasm Grading | 5 | 2021 | 258 | 0.320 |
Why?
| Adenocarcinoma | 3 | 2022 | 812 | 0.320 |
Why?
| Humans | 58 | 2023 | 118972 | 0.300 |
Why?
| Radiotherapy, Adjuvant | 2 | 2018 | 189 | 0.300 |
Why?
| Neoplasm Staging | 7 | 2021 | 1223 | 0.280 |
Why?
| Kidney Tubules, Collecting | 1 | 2005 | 27 | 0.270 |
Why?
| Clinical Competence | 1 | 2012 | 951 | 0.260 |
Why?
| Oxalic Acid | 1 | 2004 | 4 | 0.260 |
Why?
| Brachytherapy | 2 | 2016 | 103 | 0.260 |
Why?
| Urinary Bladder Neoplasms | 2 | 2021 | 211 | 0.240 |
Why?
| Aged | 21 | 2021 | 19657 | 0.210 |
Why?
| Paraganglioma | 1 | 2022 | 48 | 0.210 |
Why?
| Adrenal Gland Neoplasms | 1 | 2022 | 81 | 0.200 |
Why?
| Cell Hypoxia | 2 | 2015 | 220 | 0.200 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 4708 | 0.200 |
Why?
| Middle Aged | 20 | 2021 | 27617 | 0.200 |
Why?
| Cation Transport Proteins | 1 | 2022 | 99 | 0.200 |
Why?
| Prolactin | 3 | 1997 | 96 | 0.190 |
Why?
| Adaptor Proteins, Vesicular Transport | 2 | 1997 | 48 | 0.190 |
Why?
| Orchiectomy | 3 | 2016 | 57 | 0.190 |
Why?
| Magnetic Resonance Imaging, Interventional | 1 | 2020 | 20 | 0.190 |
Why?
| Risk Assessment | 4 | 2020 | 3057 | 0.180 |
Why?
| Salvage Therapy | 2 | 2018 | 130 | 0.180 |
Why?
| Stromal Cells | 1 | 2019 | 102 | 0.170 |
Why?
| Proanthocyanidins | 1 | 2019 | 8 | 0.170 |
Why?
| Biflavonoids | 1 | 2019 | 8 | 0.170 |
Why?
| Hospitals | 2 | 2023 | 598 | 0.170 |
Why?
| Euterpe | 1 | 2018 | 6 | 0.170 |
Why?
| Catechin | 1 | 2019 | 26 | 0.170 |
Why?
| Anthocyanins | 1 | 2019 | 30 | 0.170 |
Why?
| Neoplasm Recurrence, Local | 2 | 2018 | 900 | 0.170 |
Why?
| Androgens | 3 | 2009 | 167 | 0.170 |
Why?
| Grape Seed Extract | 1 | 2019 | 41 | 0.170 |
Why?
| Nomograms | 1 | 2019 | 48 | 0.170 |
Why?
| Digital Rectal Examination | 1 | 2018 | 10 | 0.160 |
Why?
| Urinary Tract Infections | 1 | 2019 | 136 | 0.160 |
Why?
| Reagent Kits, Diagnostic | 1 | 2018 | 42 | 0.160 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 1997 | 394 | 0.160 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 180 | 0.150 |
Why?
| Surgical Wound Infection | 2 | 2019 | 251 | 0.150 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 116 | 0.150 |
Why?
| Proton Therapy | 1 | 2017 | 10 | 0.150 |
Why?
| Neoplasm Metastasis | 5 | 2019 | 544 | 0.150 |
Why?
| Biopsy, Needle | 2 | 2016 | 190 | 0.150 |
Why?
| Seminoma | 1 | 2017 | 17 | 0.150 |
Why?
| Medical Oncology | 1 | 2019 | 229 | 0.150 |
Why?
| Plant Extracts | 1 | 2018 | 165 | 0.150 |
Why?
| Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.150 |
Why?
| Liver | 4 | 1997 | 1816 | 0.140 |
Why?
| Prognosis | 7 | 2019 | 3443 | 0.140 |
Why?
| Spectrum Analysis | 1 | 2016 | 88 | 0.140 |
Why?
| Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.140 |
Why?
| Radiology | 1 | 2019 | 199 | 0.130 |
Why?
| Radiotherapy, Conformal | 1 | 2015 | 67 | 0.130 |
Why?
| Neoplastic Stem Cells | 1 | 2019 | 336 | 0.130 |
Why?
| Lymphatic Metastasis | 3 | 2014 | 307 | 0.130 |
Why?
| Proto-Oncogene Proteins | 2 | 1997 | 618 | 0.130 |
Why?
| Risk | 2 | 2015 | 853 | 0.130 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2015 | 131 | 0.130 |
Why?
| Genomics | 1 | 2019 | 706 | 0.130 |
Why?
| Extracellular Vesicles | 1 | 2015 | 76 | 0.120 |
Why?
| Cause of Death | 1 | 2016 | 380 | 0.120 |
Why?
| Leydig Cell Tumor | 1 | 2014 | 8 | 0.120 |
Why?
| Biopsy | 4 | 2023 | 1079 | 0.120 |
Why?
| Priapism | 1 | 2013 | 9 | 0.120 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2013 | 31 | 0.120 |
Why?
| Receptors, Adrenergic, alpha | 1 | 2013 | 32 | 0.120 |
Why?
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 17 | 0.120 |
Why?
| Optics and Photonics | 1 | 2014 | 44 | 0.120 |
Why?
| Hypertension | 1 | 2022 | 1203 | 0.120 |
Why?
| Treatment Outcome | 7 | 2018 | 9342 | 0.120 |
Why?
| Proline | 1 | 2013 | 71 | 0.110 |
Why?
| Spectrometry, Fluorescence | 1 | 2014 | 173 | 0.110 |
Why?
| Triglycerides | 1 | 2015 | 519 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2010 | 127 | 0.110 |
Why?
| Neoplasm Invasiveness | 4 | 2016 | 462 | 0.110 |
Why?
| Telephone | 1 | 2013 | 152 | 0.110 |
Why?
| Drug Interactions | 1 | 2013 | 352 | 0.110 |
Why?
| Survival Rate | 4 | 2017 | 1720 | 0.100 |
Why?
| Signal Transduction | 4 | 2004 | 4709 | 0.100 |
Why?
| Attitude of Health Personnel | 1 | 2019 | 992 | 0.100 |
Why?
| Urothelium | 1 | 2011 | 33 | 0.100 |
Why?
| Lymph Nodes | 1 | 2014 | 455 | 0.100 |
Why?
| Cell Line | 3 | 2008 | 2707 | 0.100 |
Why?
| Prostatic Hyperplasia | 1 | 2011 | 38 | 0.100 |
Why?
| Postoperative Complications | 2 | 2019 | 2235 | 0.100 |
Why?
| Aged, 80 and over | 6 | 2020 | 6561 | 0.100 |
Why?
| Neoplastic Cells, Circulating | 1 | 2011 | 62 | 0.100 |
Why?
| Oxygen | 1 | 2015 | 854 | 0.100 |
Why?
| Epithelial Cells | 2 | 2008 | 963 | 0.100 |
Why?
| Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 173 | 0.090 |
Why?
| Carcinogenesis | 2 | 2022 | 182 | 0.090 |
Why?
| Decision Making | 1 | 2017 | 809 | 0.090 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2010 | 51 | 0.090 |
Why?
| Spinal Fractures | 1 | 2011 | 77 | 0.090 |
Why?
| Counseling | 1 | 2013 | 353 | 0.090 |
Why?
| Glucose | 1 | 2015 | 953 | 0.090 |
Why?
| Combined Modality Therapy | 2 | 2016 | 1166 | 0.090 |
Why?
| Survival Analysis | 2 | 2016 | 1267 | 0.090 |
Why?
| Survivors | 1 | 2013 | 418 | 0.090 |
Why?
| Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 154 | 0.090 |
Why?
| Carcinoma | 1 | 2011 | 204 | 0.090 |
Why?
| Lymph Node Excision | 2 | 2014 | 158 | 0.090 |
Why?
| Lymphatic Diseases | 1 | 2009 | 18 | 0.090 |
Why?
| Cystitis | 1 | 2009 | 21 | 0.090 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 26 | 0.080 |
Why?
| Age Factors | 4 | 2017 | 2995 | 0.080 |
Why?
| Logistic Models | 3 | 2019 | 1901 | 0.080 |
Why?
| Adult | 12 | 2020 | 31512 | 0.080 |
Why?
| Databases, Factual | 3 | 2019 | 1231 | 0.080 |
Why?
| Patient Education as Topic | 1 | 2013 | 699 | 0.080 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.080 |
Why?
| Cell Line, Tumor | 5 | 2015 | 2851 | 0.080 |
Why?
| Patient Selection | 2 | 2018 | 676 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 285 | 0.080 |
Why?
| Proportional Hazards Models | 3 | 2016 | 1125 | 0.080 |
Why?
| HSP70 Heat-Shock Proteins | 1 | 2008 | 74 | 0.080 |
Why?
| Societies, Medical | 1 | 2011 | 703 | 0.080 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 246 | 0.070 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2008 | 143 | 0.070 |
Why?
| Image-Guided Biopsy | 2 | 2020 | 34 | 0.070 |
Why?
| Time Factors | 4 | 2014 | 6412 | 0.070 |
Why?
| Kidney Tubules, Proximal | 1 | 2008 | 131 | 0.070 |
Why?
| Chemotherapy, Adjuvant | 1 | 2008 | 360 | 0.070 |
Why?
| Young Adult | 6 | 2020 | 10793 | 0.070 |
Why?
| Diagnostic Imaging | 2 | 2022 | 294 | 0.070 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 175 | 0.070 |
Why?
| Reactive Oxygen Species | 2 | 2009 | 576 | 0.070 |
Why?
| Radiotherapy Dosage | 2 | 2018 | 245 | 0.070 |
Why?
| Follow-Up Studies | 4 | 2016 | 4596 | 0.070 |
Why?
| Animals | 10 | 2022 | 33381 | 0.070 |
Why?
| Oxidative Stress | 2 | 2010 | 1178 | 0.070 |
Why?
| Mice | 4 | 2022 | 15520 | 0.070 |
Why?
| Ear, Inner | 1 | 2005 | 39 | 0.070 |
Why?
| Isoflavones | 1 | 2005 | 24 | 0.070 |
Why?
| Support Vector Machine | 2 | 2016 | 36 | 0.070 |
Why?
| History, 21st Century | 1 | 2006 | 170 | 0.070 |
Why?
| Body Fluids | 1 | 2005 | 62 | 0.070 |
Why?
| Mitotic Index | 2 | 2015 | 27 | 0.070 |
Why?
| Informed Consent | 1 | 2006 | 163 | 0.060 |
Why?
| Disease Progression | 2 | 2018 | 2490 | 0.060 |
Why?
| Cell Count | 1 | 2005 | 315 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2009 | 334 | 0.060 |
Why?
| Urinary Incontinence | 1 | 2005 | 61 | 0.060 |
Why?
| Mass Screening | 2 | 2015 | 1052 | 0.060 |
Why?
| Growth | 1 | 2004 | 58 | 0.060 |
Why?
| Propensity Score | 2 | 2016 | 242 | 0.060 |
Why?
| United States | 5 | 2019 | 12555 | 0.060 |
Why?
| Cell Proliferation | 3 | 2019 | 2275 | 0.060 |
Why?
| Receptors, Nicotinic | 1 | 2005 | 295 | 0.060 |
Why?
| Multivariate Analysis | 2 | 2017 | 1474 | 0.060 |
Why?
| Kaplan-Meier Estimate | 2 | 2016 | 842 | 0.060 |
Why?
| Protein-Tyrosine Kinases | 2 | 1997 | 407 | 0.060 |
Why?
| Transcriptional Regulator ERG | 1 | 2022 | 10 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1974 | 0.050 |
Why?
| Urinary Bladder | 1 | 2004 | 180 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 1795 | 0.050 |
Why?
| Rats, Wistar | 3 | 1997 | 399 | 0.050 |
Why?
| Serine Endopeptidases | 1 | 2022 | 105 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1047 | 0.050 |
Why?
| Testosterone | 2 | 2015 | 351 | 0.050 |
Why?
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 10 | 0.050 |
Why?
| Shc Signaling Adaptor Proteins | 2 | 1997 | 10 | 0.050 |
Why?
| Intestines | 1 | 2004 | 332 | 0.050 |
Why?
| Adolescent | 5 | 2022 | 18480 | 0.050 |
Why?
| Biomarkers, Tumor | 2 | 2020 | 1059 | 0.050 |
Why?
| Retrospective Studies | 4 | 2023 | 12978 | 0.050 |
Why?
| Oncogene Proteins, Fusion | 1 | 2022 | 181 | 0.050 |
Why?
| Inflammation | 1 | 2010 | 2566 | 0.050 |
Why?
| Reperfusion | 2 | 1996 | 43 | 0.040 |
Why?
| Feeding Behavior | 1 | 2005 | 601 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2022 | 317 | 0.040 |
Why?
| Rats | 5 | 2005 | 5392 | 0.040 |
Why?
| Quality of Life | 2 | 2013 | 2366 | 0.040 |
Why?
| Jagged-1 Protein | 1 | 2019 | 25 | 0.040 |
Why?
| Zinc | 1 | 2022 | 262 | 0.040 |
Why?
| Geography | 1 | 2019 | 190 | 0.040 |
Why?
| Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.040 |
Why?
| Receptor, Notch1 | 1 | 2019 | 65 | 0.040 |
Why?
| Spheroids, Cellular | 1 | 2019 | 56 | 0.040 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 71 | 0.040 |
Why?
| Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| Radiometry | 1 | 2018 | 45 | 0.040 |
Why?
| Kallikreins | 1 | 2018 | 33 | 0.040 |
Why?
| Janus Kinase 2 | 1 | 1997 | 32 | 0.040 |
Why?
| Enzyme Induction | 1 | 1997 | 94 | 0.040 |
Why?
| Enzyme Activation | 4 | 2008 | 828 | 0.040 |
Why?
| MAP Kinase Kinase 1 | 1 | 1997 | 67 | 0.040 |
Why?
| Carrier Proteins | 1 | 2022 | 726 | 0.040 |
Why?
| Cells, Cultured | 1 | 2005 | 4077 | 0.040 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 874 | 0.040 |
Why?
| National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.040 |
Why?
| Prospective Studies | 2 | 2020 | 6471 | 0.040 |
Why?
| Phenotype | 3 | 2010 | 3003 | 0.040 |
Why?
| Health Care Surveys | 1 | 2019 | 546 | 0.040 |
Why?
| Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| Female | 7 | 2021 | 61564 | 0.030 |
Why?
| Ultrasonography | 1 | 2020 | 716 | 0.030 |
Why?
| Protein Kinase C | 2 | 1994 | 297 | 0.030 |
Why?
| Environmental Exposure | 1 | 2019 | 405 | 0.030 |
Why?
| Altitude | 1 | 2019 | 422 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2015 | 33 | 0.030 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 47 | 0.030 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 1996 | 298 | 0.030 |
Why?
| Heterografts | 1 | 2015 | 130 | 0.030 |
Why?
| Ischemia | 2 | 1996 | 374 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 649 | 0.030 |
Why?
| Proteins | 2 | 1997 | 938 | 0.030 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 1995 | 130 | 0.030 |
Why?
| Colorado | 2 | 2015 | 4196 | 0.030 |
Why?
| Cell Movement | 1 | 2019 | 896 | 0.030 |
Why?
| Risk Factors | 2 | 2019 | 9000 | 0.030 |
Why?
| Least-Squares Analysis | 1 | 2014 | 73 | 0.030 |
Why?
| Immunohistochemistry | 2 | 2010 | 1691 | 0.030 |
Why?
| Positron-Emission Tomography | 1 | 2015 | 298 | 0.030 |
Why?
| Mice, Nude | 1 | 2015 | 663 | 0.030 |
Why?
| Needles | 1 | 2014 | 56 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2013 | 60 | 0.030 |
Why?
| SEER Program | 1 | 2014 | 205 | 0.030 |
Why?
| Radiotherapy | 1 | 2014 | 187 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 1995 | 396 | 0.030 |
Why?
| Estrogens | 1 | 2015 | 328 | 0.030 |
Why?
| Phosphorylation | 3 | 2008 | 1633 | 0.030 |
Why?
| Child | 3 | 2022 | 19129 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1995 | 359 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2015 | 940 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2015 | 477 | 0.030 |
Why?
| Equipment Design | 1 | 2014 | 519 | 0.030 |
Why?
| Reoperation | 1 | 2014 | 557 | 0.030 |
Why?
| Population Surveillance | 1 | 2014 | 413 | 0.020 |
Why?
| Life Style | 1 | 2013 | 430 | 0.020 |
Why?
| Anxiety | 1 | 2017 | 845 | 0.020 |
Why?
| Atrophy | 1 | 2010 | 164 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 310 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 296 | 0.020 |
Why?
| Feasibility Studies | 1 | 2013 | 749 | 0.020 |
Why?
| Cohort Studies | 1 | 2020 | 5116 | 0.020 |
Why?
| Aging | 2 | 2010 | 1670 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2011 | 412 | 0.020 |
Why?
| Apoptosis | 1 | 2019 | 2484 | 0.020 |
Why?
| Social Support | 1 | 2013 | 542 | 0.020 |
Why?
| Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| Metaplasia | 1 | 2009 | 57 | 0.020 |
Why?
| Imaging, Three-Dimensional | 1 | 2012 | 499 | 0.020 |
Why?
| Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 533 | 0.020 |
Why?
| Incidence | 1 | 2015 | 2424 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2013 | 1129 | 0.020 |
Why?
| Tumor Stem Cell Assay | 1 | 2008 | 35 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2020 | 3174 | 0.020 |
Why?
| Anoikis | 1 | 2008 | 35 | 0.020 |
Why?
| Adaptation, Psychological | 1 | 2013 | 557 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2009 | 138 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 1419 | 0.020 |
Why?
| Genes, Immediate-Early | 1 | 2008 | 17 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2017 | 1200 | 0.020 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 46 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| Receptors, Androgen | 1 | 2009 | 134 | 0.020 |
Why?
| Hypoglycemic Agents | 1 | 2015 | 1032 | 0.020 |
Why?
| Gonadal Steroid Hormones | 1 | 2009 | 122 | 0.020 |
Why?
| DNA, Mitochondrial | 1 | 2009 | 187 | 0.020 |
Why?
| Blotting, Western | 1 | 2010 | 1194 | 0.020 |
Why?
| Glutathione | 1 | 2009 | 324 | 0.020 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 115 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2008 | 292 | 0.020 |
Why?
| Base Sequence | 1 | 2010 | 2159 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2008 | 564 | 0.020 |
Why?
| Phosphotyrosine | 2 | 1996 | 37 | 0.020 |
Why?
| Models, Animal | 1 | 2008 | 363 | 0.020 |
Why?
| Guinea Pigs | 1 | 2005 | 151 | 0.020 |
Why?
| Equol | 1 | 2005 | 2 | 0.020 |
Why?
| Chinchilla | 1 | 2005 | 38 | 0.020 |
Why?
| Swine | 1 | 2008 | 730 | 0.020 |
Why?
| Biomarkers | 1 | 2015 | 3588 | 0.020 |
Why?
| Stress, Psychological | 1 | 2013 | 972 | 0.020 |
Why?
| Antioxidants | 1 | 2009 | 564 | 0.020 |
Why?
| Bladder Exstrophy | 1 | 2004 | 16 | 0.020 |
Why?
| Acid-Base Equilibrium | 1 | 2004 | 29 | 0.020 |
Why?
| Infant, Newborn | 1 | 2015 | 5255 | 0.020 |
Why?
| Bicarbonates | 1 | 2004 | 44 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2009 | 1384 | 0.020 |
Why?
| Meat | 1 | 2005 | 89 | 0.020 |
Why?
| Hypoxia | 1 | 2010 | 963 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2436 | 0.020 |
Why?
| Referral and Consultation | 1 | 2009 | 648 | 0.020 |
Why?
| Meningomyelocele | 1 | 2004 | 51 | 0.010 |
Why?
| Body Height | 1 | 2004 | 187 | 0.010 |
Why?
| Infant | 1 | 2015 | 8293 | 0.010 |
Why?
| Child, Preschool | 1 | 2015 | 9491 | 0.010 |
Why?
| Bone Density | 1 | 2004 | 449 | 0.010 |
Why?
| RNA, Messenger | 1 | 2008 | 2657 | 0.010 |
Why?
| Neoplasms | 1 | 2013 | 2179 | 0.010 |
Why?
| Gene Expression Regulation | 1 | 2008 | 2445 | 0.010 |
Why?
| Mutation | 1 | 2009 | 3457 | 0.010 |
Why?
| Neurons | 1 | 2005 | 1345 | 0.010 |
Why?
| GRB2 Adaptor Protein | 1 | 1996 | 12 | 0.010 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 46 | 0.010 |
Why?
| Sialoglycoproteins | 1 | 1996 | 162 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 1996 | 155 | 0.010 |
Why?
| Receptors, Interleukin-1 | 1 | 1996 | 228 | 0.010 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 256 | 0.010 |
Why?
| Lymphocyte Count | 1 | 1995 | 136 | 0.010 |
Why?
| Densitometry | 1 | 1994 | 30 | 0.010 |
Why?
| Phosphotransferases | 1 | 1994 | 27 | 0.010 |
Why?
| Precipitin Tests | 1 | 1994 | 93 | 0.010 |
Why?
| CD4 Lymphocyte Count | 1 | 1995 | 267 | 0.010 |
Why?
| Injections, Intraperitoneal | 1 | 1994 | 108 | 0.010 |
Why?
| Ornithine Decarboxylase | 1 | 1994 | 12 | 0.010 |
Why?
| Genes, myc | 1 | 1994 | 46 | 0.010 |
Why?
| Molecular Weight | 1 | 1994 | 343 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 332 | 0.010 |
Why?
| Cytosol | 1 | 1994 | 221 | 0.010 |
Why?
| Immunoblotting | 1 | 1994 | 307 | 0.010 |
Why?
| Substrate Specificity | 1 | 1994 | 371 | 0.010 |
Why?
| Tyrosine | 1 | 1994 | 233 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 1624 | 0.010 |
Why?
| Interleukin-1 | 1 | 1996 | 980 | 0.010 |
Why?
| Gene Expression | 1 | 1994 | 1489 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 1994 | 1284 | 0.000 |
Why?
| T-Lymphocytes | 1 | 1995 | 1774 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|